Sands Capital

Hawk is an award-winning provider of AI-supported anti-money laundering and fraud detection technology. Banks, payment providers, and fintechs globally are using Hawk’s powerful combination of traditional rules and explainable AI to improve the effectiveness of their AML compliance and fraud prevention. Hawk monitors and screens billions of transactions across 60 countries evey year.

Flock Safety specializes in security solutions centered around automated license plate recognition (ALPR) cameras, which are utilized by neighborhoods, law enforcement agencies, and businesses. Their primary product captures and analyzes vehicle license plates to aid in crime prevention and resolution. The system not only helps local law enforcement by providing critical data during investigations but also proactively alerts them when stolen vehicles enter monitored areas. This technology fosters community engagement, allowing residents to assist in maintaining safety by sharing relevant information with police. By integrating the efforts of communities, schools, and law enforcement, Flock Safety aims to create safer environments while prioritizing privacy and data protection.

CompScience is a technology company that specializes in AI-driven solutions for workers' compensation insurance, emphasizing workplace safety through data analysis and risk identification. The platform aids organizations in evaluating their safety protocols, pinpointing potential hazards, and implementing effective risk management strategies. By utilizing machine learning algorithms, CompScience analyzes historical data to forecast future incidents and suggest preventive measures, ultimately helping businesses lower claims costs and enhance employee safety. Furthermore, the platform fosters communication between safety teams and management, ensuring that safety initiatives align with organizational objectives. It also serves logistics and manufacturing sectors by providing actionable insights, safety monitoring, and a user-friendly dashboard, contributing to measurable reductions in injuries and workers' compensation costs while improving overall performance and employee satisfaction.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.

Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.

Anduril Industries is a defense technology company that designs, manufactures, and deploys advanced hardware and software products to address complex national security challenges for the United States and its allies. Founded in 2017 and headquartered in Irvine, California, the company specializes in developing cutting-edge solutions, including the Lattice Platform—an artificial intelligence system that integrates real-time data into a cohesive operational picture—and the Sentry Tower, which consolidates data from various electromagnetic sources. Additionally, Anduril produces the Ghost sUAS, a man-portable unmanned aerial system capable of executing numerous missions autonomously, and the Anvil sUAS, designed for precision interception of drone threats with human operator verification. Through its innovative technologies, Anduril aims to enhance military capabilities and border surveillance, ensuring the safety and effectiveness of those serving in defense of national interests.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Founded in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on creating enterprise voice assistants capable of engaging in natural conversations with customers. These assistants utilize advanced machine learning and natural language processing to understand and respond to customer inquiries, regardless of phrasing or dialect. The platform supports features such as multilingual capabilities, data acquisition, and dynamic flow design, facilitating the creation of human-like interactions and improving customer service experiences across various industries.

Ramp is a company that specializes in providing modern solutions for financial operations and enterprise content delivery. Its financial platform includes tools for corporate card management, expense tracking, bill payments, and seamless accounting integrations, aimed at helping organizations optimize their financial tasks and reduce costs. Additionally, Ramp offers advanced video management and delivery software, enabling companies to enhance video content discovery, user engagement, and secure delivery. Its products, such as VideoVerge and AltitudeCDN, leverage innovative technologies like speech-to-text and natural language processing to create rich metadata for video assets, allowing them to be effectively integrated into popular content management systems. Ramp serves a diverse clientele, including prominent media companies and organizations across various industries such as healthcare, finance, and technology. Founded in 1948 and based in Boston, Massachusetts, Ramp operates as a subsidiary of Raytheon BBN Technologies Corporation.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

HealthSnap, Inc. is a healthcare technology company that specializes in developing solutions for processing patient lifestyle data to enhance healthcare delivery. Incorporated in 2015 and headquartered in Miami, Florida, with an additional office in San Mateo, California, HealthSnap offers a comprehensive Virtual Care Management Platform. This platform integrates various services, including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM), to assist healthcare organizations in improving patient outcomes, reducing healthcare utilization, and diversifying revenue streams. By utilizing data from wearables, remote sensors, and patient questionnaires, HealthSnap's platform enables effective care coordination and automated management of chronic conditions, empowering clinicians with the necessary tools to prevent and manage lifestyle-related diseases efficiently.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Ramp is a company that specializes in providing modern solutions for financial operations and enterprise content delivery. Its financial platform includes tools for corporate card management, expense tracking, bill payments, and seamless accounting integrations, aimed at helping organizations optimize their financial tasks and reduce costs. Additionally, Ramp offers advanced video management and delivery software, enabling companies to enhance video content discovery, user engagement, and secure delivery. Its products, such as VideoVerge and AltitudeCDN, leverage innovative technologies like speech-to-text and natural language processing to create rich metadata for video assets, allowing them to be effectively integrated into popular content management systems. Ramp serves a diverse clientele, including prominent media companies and organizations across various industries such as healthcare, finance, and technology. Founded in 1948 and based in Boston, Massachusetts, Ramp operates as a subsidiary of Raytheon BBN Technologies Corporation.

OneTrust, LLC is a technology company that specializes in privacy management and compliance solutions, assisting organizations in adhering to global regulations. Founded in 2016 and headquartered in Atlanta, Georgia, OneTrust offers a comprehensive platform that automates privacy impact assessments, data inventory mapping, and risk remediation actions. Its solutions cover a wide range of needs, including vendor risk management, incident reporting, and website compliance, helping businesses manage privacy risks associated with customer, employee, and vendor data. The platform enables collaboration among privacy professionals and business groups, facilitating continuous compliance through recurring audits and assessments. OneTrust serves a diverse clientele, from multinational corporations to small and medium enterprises, and operates additional offices in various global locations, including London, São Paulo, and Bengaluru.

Hungry Marketplace Inc. is a Washington, D.C.-based platform that connects independent chefs with businesses seeking high-quality catered meals. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, the company aims to revolutionize the $60 billion business and events catering market by offering a diverse range of curated menus from local chefs. Hungry's platform facilitates the ordering of office lunches and other meal services. The company is committed to community welfare through its 'Fight Against Hunger' initiative, which donates one meal for every two purchased, and its 'WeRecycle' program, which emphasizes environmental sustainability by using biodegradable serving materials. With operations expanding rapidly in cities such as Philadelphia, Atlanta, Boston, and New York City, Hungry aims to broaden its reach to a total of 23 U.S. cities by the end of 2021.

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

Hawk is an award-winning provider of AI-supported anti-money laundering and fraud detection technology. Banks, payment providers, and fintechs globally are using Hawk’s powerful combination of traditional rules and explainable AI to improve the effectiveness of their AML compliance and fraud prevention. Hawk monitors and screens billions of transactions across 60 countries evey year.

Snyk Ltd. is a software as a service company that provides a platform for identifying, fixing, and monitoring vulnerabilities in applications. Founded in 2015 and headquartered in London, with additional offices in Tel Aviv, Boston, and Ontario, Snyk offers a range of solutions tailored for developers and security teams. Its key products include Snyk Code, a developer-first static application security testing tool, and container vulnerability management for securing Docker images. The platform also supports application security management, licensing compliance, and infrastructure as code security, ensuring that all components of modern applications are secure. Snyk’s Developer Security Platform integrates seamlessly into developers' workflows, promoting collaboration between development and security teams. The company serves over 1,200 customers globally, including notable organizations like Google and Salesforce, and has formed a strategic partnership with Rapid7. Snyk is recognized for its contributions to enhancing application security in an increasingly digital landscape.

Tellius, Inc. is an AI-powered business analytics platform established in 2015 and headquartered in Reston, Virginia. The platform is designed to help enterprises accelerate data-driven insights and decision-making by integrating artificial intelligence with a search-enabled interface for ad hoc exploration. Unlike traditional business intelligence tools, Tellius employs a distributed architecture that leverages Apache Spark, enabling it to handle big data efficiently. The platform automates the interpretation and analysis of data through machine learning, identifying hidden correlations, trends, and anomalies. Users can pose questions about their business data and receive immediate insights, which are presented as suggested visualizations and predictive models, facilitating a more comprehensive understanding of their operations.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

RedBud Brands is a brand development studio bringing people, ideas, and capital together to create disruptive new companies with an emphasis on the consumer space. It is an innovative venture platform for launching impactful brands that partners with visionary founders and executives to support and supercharge the creation of transformative, valuable, and sustainable companies. The company focuses primarily on premium, consumer packaged goods sectors with an emphasis on 'better-for-you' products.

Credo AI is focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. The company offers an AI governance platform that automates oversight and risk management, ensuring compliance with emerging global standards such as the EU AI Act and NIST. Founded in 2020, Credo AI's platform supports organizations in measuring, monitoring, and managing risks associated with AI, which helps build customer trust and unlock sales opportunities. By prioritizing human control over AI technologies, Credo AI aims to enhance both business outcomes and societal benefits. The company has received recognition in the industry, including listings in CBInsights AI 100 and accolades from the World Economic Forum and Fast Company.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Red Sift is a cybersecurity company that focuses on enhancing digital resilience for organizations by addressing vulnerabilities across their entire digital footprint. Through its Digital Resilience Platform, Red Sift provides tools for discovering and monitoring threats related to email, domains, brands, and network perimeters. The platform features sophisticated remediation capabilities that help organizations combat phishing attacks and maintain compliance with security protocols. Red Sift serves a diverse range of clients, including well-known companies such as Domino’s and ZoomInfo, and is recognized as a trusted partner of major firms like Entrust and Microsoft. With offices in North America, Australia, Spain, and the UK, Red Sift leverages machine learning to analyze data from core business processes, empowering users to better manage their online security challenges.

Speech Graphics Ltd, founded in 2010 and based in Edinburgh, United Kingdom, specializes in procedural facial animation solutions for the entertainment industry. The company offers SGX, a software that transforms audio files and transcripts into high-quality facial animations without the need for motion capture. Its technology has been utilized in various productions, including AAA video games and music videos, and serves applications in communication and training. The firm emerged from the University of Edinburgh's School of Informatics and has collaborated with notable clients such as Warner Brothers and Def Jam Recordings. Speech Graphics has garnered several awards for its innovative technology, including the John Logie Baird Award, and has received development grants from organizations like Scottish Enterprise.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Codoxo, previously known as Fraudscope, specializes in developing an AI-assisted platform aimed at enhancing the efficiency and affordability of healthcare systems. The company employs a patented algorithm to detect fraud, waste, and abuse within healthcare plans, enabling earlier identification of suspicious activities compared to traditional methods. This innovative approach supports investigators and analysts in deriving insights and conducting comprehensive investigations of questionable claims. By focusing on these critical areas, Codoxo helps ensure that healthcare resources are allocated effectively, ultimately contributing to improved patient care.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.

Upgrade, Inc. is an online lending platform based in San Francisco, California, with additional offices in Phoenix, Montreal, and Chicago. Founded in 2016, Upgrade provides access to personal loans and the Upgrade Card, offering consumers affordable credit options. The Upgrade Card combines the benefits of traditional credit cards with the responsible lending characteristics of installment loans, available at numerous retail locations in the U.S. In addition to lending services, Upgrade offers free credit monitoring, alerts, and educational tools designed to help consumers understand and manage their finances effectively. By combining financial products with educational resources, Upgrade aims to promote responsible credit use among mainstream consumers.

Ankyra is a biotechnology company focused on developing anchored immunotherapy for cancer treatment. The company addresses the limitations of traditional cytokine therapies, which are often restricted due to widespread immune activation and associated toxicity. Ankyra's innovative approach involves the use of its Anchored Immunotherapy Platform to create ANK-101, a stable complex of a modified IL-12 cytokine and aluminum hydroxide, an FDA-approved adjuvant. This combination allows for targeted intratumoral delivery, enhancing the localized retention and activity of IL-12 while reducing systemic side effects. By optimizing the therapeutic potential of anchored immunotherapy, Ankyra aims to improve treatment outcomes for cancer patients, offering a safer and more effective alternative to conventional therapies.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

Bridgit Inc. is a Canadian company that specializes in developing construction project management solutions. Founded in 2014 and headquartered in Kitchener, Bridgit offers two primary products: Bridgit Bench, a workforce management and resource planning tool, and Bridgit Field, which focuses on inspection, task, and communication management. The company's mission is to enhance profitability in the construction industry through a people-first approach, transforming workforce data into actionable insights that support strategic and tactical decision-making. Bridgit serves a range of clients, including major construction firms such as Skanska and Balfour Beatty. The company has successfully raised over $35 million in equity financing from various investors, including Autodesk and Salesforce Ventures, enabling it to expand its offerings and support contractors and developers in managing their operations more efficiently.

Hungry Marketplace Inc. is a Washington, D.C.-based platform that connects independent chefs with businesses seeking high-quality catered meals. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, the company aims to revolutionize the $60 billion business and events catering market by offering a diverse range of curated menus from local chefs. Hungry's platform facilitates the ordering of office lunches and other meal services. The company is committed to community welfare through its 'Fight Against Hunger' initiative, which donates one meal for every two purchased, and its 'WeRecycle' program, which emphasizes environmental sustainability by using biodegradable serving materials. With operations expanding rapidly in cities such as Philadelphia, Atlanta, Boston, and New York City, Hungry aims to broaden its reach to a total of 23 U.S. cities by the end of 2021.

Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

JumpCloud, Inc. operates a Directory-as-a-Service platform that simplifies identity management and securely connects users to their systems, applications, files, and networks. The platform enables organizations to manage user accounts, permissions, and device access while automating critical server management tasks such as security, compliance, and configuration. With its cloud-based directory, JumpCloud provides a single solution for IT and security teams to authenticate and manage user identities across diverse environments, applying Zero Trust principles to enhance security. The company serves over 100,000 organizations globally, including notable clients like Cars.com and GoFundMe. Founded in 2010 and based in Louisville, Colorado, JumpCloud was initially known as SafeInstance, Inc. before rebranding in 2013.

Snyk Ltd. is a software as a service company that provides a platform for identifying, fixing, and monitoring vulnerabilities in applications. Founded in 2015 and headquartered in London, with additional offices in Tel Aviv, Boston, and Ontario, Snyk offers a range of solutions tailored for developers and security teams. Its key products include Snyk Code, a developer-first static application security testing tool, and container vulnerability management for securing Docker images. The platform also supports application security management, licensing compliance, and infrastructure as code security, ensuring that all components of modern applications are secure. Snyk’s Developer Security Platform integrates seamlessly into developers' workflows, promoting collaboration between development and security teams. The company serves over 1,200 customers globally, including notable organizations like Google and Salesforce, and has formed a strategic partnership with Rapid7. Snyk is recognized for its contributions to enhancing application security in an increasingly digital landscape.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Founded in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on creating enterprise voice assistants capable of engaging in natural conversations with customers. These assistants utilize advanced machine learning and natural language processing to understand and respond to customer inquiries, regardless of phrasing or dialect. The platform supports features such as multilingual capabilities, data acquisition, and dynamic flow design, facilitating the creation of human-like interactions and improving customer service experiences across various industries.

Qvella Corporation is a molecular diagnostics company based in Toronto, Canada, focused on revolutionizing clinical microbiology through innovative technologies. Founded in 2009 by a group of scientists and engineers, the company aims to significantly reduce the time required to obtain results for microbiological tests. Qvella's flagship technology, known as Field Activated Sample Treatment (FAST™), employs a unique electrical lysing and sample treatment method called e-lysis™. This approach allows for the rapid and direct detection of infectious agents from unenriched biological samples, such as whole blood, without the need for extensive sample processing. By delivering actionable results in clinically relevant time frames, Qvella's technology seeks to enhance patient outcomes and improve the overall practice of medicine.

#Paid is a technology company that provides a creative marketing platform designed to connect brands with social media creators for collaborative campaigns. The platform facilitates partnerships between brands and relevant creators, including artists, travelers, storytellers, and photographers, to enhance product placement on social media. By transforming creator-generated content into paid advertisements, #Paid enables authentic and engaging collaborations that allow brands to effectively reach their target audiences through the creators' established followings.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Gusto is a software-as-a-service (SaaS) company focused on Human Capital Management (HCM). It offers a comprehensive, cloud-based platform that provides a range of HR and payroll services designed for small businesses. Key features of Gusto’s platform include payroll processing, benefits administration, time and attendance tracking, and employee onboarding. Additionally, it supports the management of employee benefits such as health, dental, and vision insurance. By streamlining these essential functions, Gusto aims to simplify the complexities of human resource management, enabling businesses to effectively meet their employees' needs.

Exo is a medical device startup focused on developing a handheld ultrasound platform for imaging and therapeutic applications. The company aims to provide affordable and user-friendly medical imaging solutions for healthcare professionals globally. By integrating advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost efficiencies of semiconductor manufacturing, Exo significantly lowers the costs associated with medical imaging. This technology allows healthcare providers to make vital, real-time decisions that enhance patient outcomes. Exo's commitment to high-quality, accessible imaging represents a significant advancement in medical technology, making effective diagnostic tools available at an unprecedented price point.

Blackbuck, founded in 2015, is a leading online platform in India that connects shippers with truck operators, transforming the logistics landscape through technology. The company focuses on streamlining the trucking process by facilitating load bookings, offering price discovery, route optimization, and in-transit tracking. This comprehensive approach not only enhances operational efficiency for shippers and truckers but also supports the livelihoods of many individuals within the transportation ecosystem. Blackbuck's commitment to reliability and efficiency has positioned it as the largest trucking network in India, backed by a strong team and notable investors. The company has received multiple accolades, including the 'Young Turks Startup of the Year' award and recognition as 'Company of the Year - Logistics' in 2018. Additionally, Blackbuck's innovative business model has been featured in a Harvard Business School case study.

Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.

Primer is an internet company that specializes in utilizing artificial intelligence to analyze extensive text data. By employing machine learning and natural language processing, Primer's platform automates the examination of large datasets, allowing businesses to efficiently parse and collate documents in multiple languages. This technology enables users to uncover insights and generate reports that are comparable to those produced by human analysts. Through its innovative approach, Primer aims to help organizations bridge the intelligence gap and enhance their understanding of complex information, thus facilitating informed decision-making and fostering the ability to respond to emerging trends.

Nubank is a prominent digital bank revolutionizing finance with its customer-centric approach. It provides a variety of services, including credit cards, personal loans, and digital payments, all accessible through a simple mobile app. Known for transparency, ease of use, and low fees, Nubank aims to empower users with innovative solutions for better financial management.

Outreach Inc. is a sales engagement platform that enhances revenue growth by optimizing customer interactions across various channels, including email, voice, and social media. Founded in 2011 and headquartered in Seattle, with an office in London, the company offers solutions for account-based, outbound, and inbound sales, as well as customer retention and expansion. Its platform employs machine learning to automate repetitive tasks, track sales statistics, and provide insights into buyer sentiment, allowing sales teams to tailor their approaches based on real-time emotive signals. Outreach's client base includes prominent companies such as Zoom, Adobe, and Microsoft, who utilize the platform to improve the efficiency and effectiveness of their sales processes, ultimately driving predictable and measurable growth.

Lyra Health, Inc. is a digital health company based in Burlingame, California, founded in 2015. It operates a platform that connects employers with a curated network of mental health care providers, including therapists and coaches. Lyra's innovative technology matches employees to the appropriate mental health resources based on their individual needs and preferences, enhancing access to high-quality care. The platform employs clinical measures to assess symptom improvement for common mental health issues, leading to significantly better outcomes compared to traditional plans. By offering live video therapy, coaching, and digital self-care tools, Lyra facilitates a comprehensive treatment journey for its members, resulting in increased engagement and support throughout the mental health process.

Boom Entertainment is a technology company that develops a sports gaming application tailored for the sports betting industry. The application focuses on casual gaming experiences and is designed to support both real money and free-to-play formats. By collaborating with professional sports leagues, media companies, and casino operators, Boom Entertainment promotes custom gaming experiences that cater to a diverse audience. The company's innovative products are aimed at large gaming, media, and entertainment firms, facilitating business-to-business solutions that enable Tier I casino operators to offer real-money gaming options.

Tellius, Inc. is an AI-powered business analytics platform established in 2015 and headquartered in Reston, Virginia. The platform is designed to help enterprises accelerate data-driven insights and decision-making by integrating artificial intelligence with a search-enabled interface for ad hoc exploration. Unlike traditional business intelligence tools, Tellius employs a distributed architecture that leverages Apache Spark, enabling it to handle big data efficiently. The platform automates the interpretation and analysis of data through machine learning, identifying hidden correlations, trends, and anomalies. Users can pose questions about their business data and receive immediate insights, which are presented as suggested visualizations and predictive models, facilitating a more comprehensive understanding of their operations.

Biosplice Therapeutics is engaged in the research and development of therapeutic drugs aimed at tissue-level regeneration, with a focus on osteoarthritis and oncology. The company utilizes a platform that originated from small molecule-based modulation of the Wnt pathway, enabling the discovery of new biological targets and processes. This innovative approach allows Biosplice to develop therapeutics that address a variety of degenerative diseases, aiming to create effective treatments for conditions that currently lack adequate options. By concentrating on regenerative medicine, the company aspires to improve patient health through the advancement of new curative therapies.

Snyk Ltd. is a software as a service company that provides a platform for identifying, fixing, and monitoring vulnerabilities in applications. Founded in 2015 and headquartered in London, with additional offices in Tel Aviv, Boston, and Ontario, Snyk offers a range of solutions tailored for developers and security teams. Its key products include Snyk Code, a developer-first static application security testing tool, and container vulnerability management for securing Docker images. The platform also supports application security management, licensing compliance, and infrastructure as code security, ensuring that all components of modern applications are secure. Snyk’s Developer Security Platform integrates seamlessly into developers' workflows, promoting collaboration between development and security teams. The company serves over 1,200 customers globally, including notable organizations like Google and Salesforce, and has formed a strategic partnership with Rapid7. Snyk is recognized for its contributions to enhancing application security in an increasingly digital landscape.

Luminoah is a medical device company focused on enhancing chronic disease care through its innovative enteral nutrition platform. The company has developed a wearable system that integrates durable medical equipment with consumable nutrition pouches. This platform allows for personalized enteral feeding, enabling doctors to remotely monitor patients and track feeding status online. By combining technology and nutrition, Luminoah aims to revolutionize the enteral feeding market and improve clinical outcomes for individuals requiring nutritional support.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

WireWheel, Inc. is a software company that offers a data privacy management platform designed to assist organizations in complying with data protection regulations such as the EU GDPR, Privacy Shield, PCI DSS, and HIPAA. Founded in 2016 and based in Arlington, Virginia, WireWheel provides cloud-based solutions that help global enterprises operationalize privacy and become GDPR-ready. The platform includes features for privacy program management and subject rights request management, leveraging machine learning and data science to enhance its effectiveness. Additionally, it facilitates the automatic mapping of public cloud assets and the management of third-party relationships, helping companies navigate compliance obligations while maximizing the potential of their data assets for competitive advantage.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

StockX LLC operates an online marketplace that facilitates the buying and selling of limited edition and high-demand sneakers. Founded in March 2015 and headquartered in Detroit, Michigan, StockX provides a platform that mimics a stock market environment, allowing users to engage in anonymous transactions with stock market-like visibility. The marketplace offers features such as historical price and volume metrics, real-time bids and offers, and time-stamped trades. Users can create personalized sneaker portfolios by uploading their current collections, enabling them to compare and contrast their sneakers with those of other users. This structure empowers consumers to assess the value of their products while ensuring sellers receive fair deals through transparent market analysis and insights.

Uhnder is a start-up developing products for sensing, cognition, and communication for the Internet of Things (IoT) market. It is headquartered in California with engineering and operations based in Austin and St. Louis. Uhnder develops a digital automotive radar-on-chip designed to automate systems for safety and better feedback response. Uhnder disrupts the autonomous vehicle business with what it says is a more accurate and reliable alternative to light detection and ranging, known as lidar, which is one of the most common technologies used to make vehicles more aware of their surroundings. Uhnder's chip helps to avoid collisions, alerts to potential problems, helps with quick localization, as electronic fences for navigation and localization and for communication.

Papercup is a London-based company that specializes in automating the dubbing and translation of video content using advanced artificial intelligence. Its software employs a combination of Bayesian neural networks and speech synthesis to create synthetic voice-overs that closely resemble human speech. This technology allows video creators to produce content in their original language while enabling users to translate videos into their preferred languages. Papercup's platform streamlines the localization process, making it faster and more cost-effective compared to traditional methods. The company also incorporates a quality assurance system where professional translators review the voiceovers, ensuring high accuracy and broadcast-quality results. By enhancing video accessibility, Papercup aims to help content owners engage with a global audience more effectively.

Brightflag is a provider of AI-powered software designed to help organizations manage their legal expenses efficiently. Founded in 2014, the company processes billions of dollars in legal spend annually, resulting in significant savings and reduced administrative workload for clients. Brightflag's platform offers features for matter management, e-billing reporting, and analytics, utilizing advanced language analysis technologies to evaluate legal invoices. This enables clients to identify cost-saving opportunities and gain visibility into their legal spending, streamlining the approval process for legal invoices. With a global presence in Dublin, New York, and Sydney, Brightflag serves in-house legal teams and their vendors, offering user-friendly solutions backed by proactive customer support.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which is designed to selectively target amyloid-beta oligomers, believed to be a key factor in the progression of Alzheimer's disease. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in the enrollment of patients for clinical trials. The Phase 1 clinical trial for ACU193 began in 2021, aiming to assess its safety, tolerability, and pharmacokinetics in patients with mild cognitive impairment and mild dementia resulting from Alzheimer's disease. Founded in 1996 and based in Livermore, California, Acumen Pharmaceuticals is committed to addressing the challenges posed by Alzheimer’s disease through innovative therapeutic approaches.

Scopely, Inc. is an interactive entertainment and video game company based in Culver City, California, founded in 2011. It specializes in developing and publishing mobile and tablet games for both casual and core gamers globally. Scopely is known for its popular franchises, such as "Star Trek™ Fleet Command," "MARVEL Strike Force," "Stumble Guys," and "Yahtzee With Buddies." The company utilizes its proprietary technology platform, Playgami™, to create immersive gaming experiences, with a focus on player engagement and long-lasting enjoyment. Scopely also offers a range of services including game design, live operations, marketing, and analytics, supporting a diversified portfolio within the mobile gaming industry. With operations in various international markets, including Asia-Pacific, EMEA, and North America, Scopely has established itself as a significant player in the interactive entertainment sector.

BYJU'S is a prominent global ed-tech company founded in India in 2011, dedicated to providing engaging and effective learning solutions to over 150 million students worldwide. Its mission focuses on making high-quality education accessible, with a diverse range of offerings that include BYJU's: The Learning App and other brands like Disney-BYJU's Early Learn and BYJU's FutureSchool. The company's platform utilizes original content, watch-and-learn videos, animations, and interactive simulations to create a personalized educational experience that adapts to each student's unique learning style and pace. With a team of over 12,000 teachers, BYJU'S supports pre-K–12 education and various competitive exams, employing innovative methods that enhance engagement. The company has established partnerships with major firms such as Disney and Google to expand its reach and impact. Headquartered in India, BYJU'S operates in more than 21 countries, offering learning programs in over eight languages, and has made significant acquisitions to broaden its educational footprint.

Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.